Based on our findings, the inhibition of IRE1α seems to be the most promising approach in ARMS, whereas others indicate that the inhibition of PERK could be a strategy of interest in ERMS [24]. The gene discussed is ERN1; the disease is embryonal rhabdomyosarcoma.